Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of 2028 Expanded ongoing collaboration with Almirall, with election of a second target focused on dermatological indications VANCOUVER, Wash. and NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with ...
Shenandoah Telecommunications Wins Prestigious CableFax Top Ops Work Culture Award EDINBURG, Va., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (“Shentel”) (Nasdaq: SHEN) has been honored with the 2025 CableFax Top Ops Award for Work Culture. Each year, the Top Ops Awards recognize the outstanding achievements of leading cable operators across 15 categories. The Work Culture category celebrates organizations that work to improve the lives of their employees and foster an environment of connection among colleagues and with the company itself. “We are grateful to...
Two Directors at Centene Corp bought 19,512 shares at between 0.000USD and 25.500USD. The significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target Almirall selects second target in AI Drug Creation collaborationExpanded collaboration builds on Absci’s successful de novo molecule design for difficult‑to‑drug targets in the first stage of the collaboration with Almirall BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with...
Shenandoah Telecommunications Appoints Edward H. “Ed” McKay as President & CEO, Christopher E. French Transitions to New Role as Executive Chairman EDINBURG, Va., July 31, 2025 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (“Shentel” or the “Company”) (Nasdaq: SHEN) announced today that its Board of Directors has appointed Edward H. “Ed” McKay as President and Chief Executive Officer (“CEO”). Christopher E. French, Shentel’s current President and CEO, will step into the role of Executive Chairman of the Board and remain active in steering the Company’s strategy while continuin...
Shenandoah Telecommunications Company Reports Second Quarter 2025 Results EDINBURG, Va., July 31, 2025 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (“Shentel” or the “Company”) (Nasdaq: SHEN) announced second quarter 2025 financial and operating results. Second Quarter 2025 Highlights Glo Fiber Expansion Markets1 data subscribers grew 43.1% compared to the second quarter of 2024 to approximately 76,000. Glo Fiber Expansion Markets revenue grew 40.5% compared to the second quarter of 2024 to $19.8 million. Total revenue grew 3.2% compared to the second quarter of 2024 to $...
A director at Enterprise Products Partners LP bought 16,000 shares at 31.554USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025 VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will report business updates and financial and operating results for the second quarter 2025 after market close on Tuesday, August 12, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacifi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.